Compass Therapeutics (CMPX) Price & Analysis

Compare

417 Followers

CMPX Stock Chart & Stats

$5.39

$0.48(33.57%)

At close: Jan 08 4:00 PM EST

$5.39

$0.48(33.57%)

Day’s Range― - ―

52-Week Range$1.33 - $5.86

Previous CloseN/A

Volume16.21M

Average Volume (3M)1.94M

Market Cap

$933.78M

Enterprise Value$380.71M

Total Cash (Recent Filing)$219.90M

Total Debt (Recent Filing)$9.87M

Price to Earnings (P/E)―

Beta2.01

Next Earnings

Feb 27, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding177,862,100

10 Day Avg. Volume1,579,613

30 Day Avg. Volume1,942,761

Financial Highlights & Ratios

PEG Ratio-0.44

Price to Book (P/B)1.59

Price to Sales (P/S)233.89

P/FCF Ratio-4.43

Enterprise Value/Market Cap0.41

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-5.54

Forecast

1Y Price Target

$14.00

Price Target Upside159.74% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-0.43

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessesThe company announced positive pivotal topline results from the COMPANION-002 study of tovecimig in combination with paclitaxel in patients with advanced BTC.

Earnings And Financial GuidanceCMPX reported earnings results including modestly updated guidance around multiple pipeline programs.

Regulatory And Market OpportunitiesThe company has FDA Fast Track Designation for tovecimig in biliary tract cancer.

Bears Say

Compass Therapeutics News

Canaccord starts Compass Therapeutics with a Buy ahead of tovecimig readout

As previously reported, Canaccord initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $10 price target...

11d ago

CMPX

Compass Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Li Watsek initiated coverage of Compass Therapeutics (CMPX) with an Overweight rating and no price...

11d ago

CMPX

Compass Therapeutics initiated with a Buy at Canaccord

Canaccord analyst John Newman initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $10 price target...

11d ago

CMPX

Compass Therapeutics initiated with an Outperform at Citizens JMP

Citizens JMP analyst Reni Benjamin initiated coverage of Compass Therapeutics (CMPX) with an Outperform rating and $10 price...

11d ago

CMPX

Compass Therapeutics’ CTX-10726: A Promising Leader in the Competitive PD-1 and VEGF Markets

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Compass Therapeutics today and set a price target...

1M ago

CMPX

Compass Therapeutics Reports Q3 2025 Financial Results

Compass Therapeutics, Inc. ( ($CMPX) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

CMPX

Positive Outlook for Compass Therapeutics: Buy Rating Justified by Promising Developments and Strong Financial Position

LifeSci Capital analyst Charles Zhu has maintained their bullish stance on CMPX stock, giving a Buy rating on...

1M ago

CMPX

Compass Therapeutics reports Q3 EPS (8c), consensus (13c)

“We have made strong progress across our clinical pipeline this quarter and based on a continuing trend of...

1M ago

CMPX

Compass Therapeutics presents preclinical data on CTX-10726

Compass Therapeutics (CMPX) announced its poster presentation at the 40th Society for Immunotherapy of Cancer, SITC, Annual Meeting,...

1M ago

CMPX

Compass Therapeutics’ Phase 1 Study of CTX-8371: A Potential Game-Changer in Cancer Treatment

Compass Therapeutics, Inc. (($CMPX)) announced an update on their ongoing clinical study. Compass Therapeutics, Inc. is conducting a...

2M ago

CMPX

Compass Therapeutics management to meet with Piper Sandler

Meeting to be held in New York on October 23-27 hosted by Piper Sandler. Published first on TheFly...

2M ago

CMPX

Promising Outlook for Compass Therapeutics: Buy Rating Backed by COMPANION-002 Trial Success and Market Potential

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Compass Therapeutics and keeping the price target...

2M ago

CMPX

Buy Rating for Compass Therapeutics Driven by Promising Clinical Trial Data and Strategic Enrollment

Compass Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Charles Zhu from...

2M ago

CMPX

Compass Therapeutics initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Compass Therapeutics (CMPX) with an Outperform rating and $10 price target Published first...

2M ago

CMPX

CMPX FAQ

What was Compass Therapeutics’s price range in the past 12 months?

Compass Therapeutics lowest stock price was $1.33 and its highest was $5.86 in the past 12 months.

What is Compass Therapeutics’s market cap?

Compass Therapeutics’s market cap is $933.78M.

When is Compass Therapeutics’s upcoming earnings report date?

Compass Therapeutics’s upcoming earnings report date is Feb 27, 2026 which is in 75 days.

How were Compass Therapeutics’s earnings last quarter?

Compass Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.139 by $0.059.

Is Compass Therapeutics overvalued?

According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Compass Therapeutics pay dividends?

Compass Therapeutics does not currently pay dividends.

What is Compass Therapeutics’s EPS estimate?

Compass Therapeutics’s EPS estimate is -0.09.

How many shares outstanding does Compass Therapeutics have?

Compass Therapeutics has 177,862,100 shares outstanding.

What happened to Compass Therapeutics’s price movement after its last earnings report?

Compass Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.139. Following the earnings report the stock price went up 0.792%.

Which hedge fund is a major shareholder of Compass Therapeutics?

Currently, no hedge funds are holding shares in CMPX

Compass Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-37.82%

Trailing 12-Months

Asset Growth

55.05%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Compass Therapeutics

Compass Therapeutics (CMPX) is a clinical-stage biotechnology company focused on developing and commercializing next-generation antibody therapeutics. The company operates in the biopharmaceutical sector, concentrating on innovative treatments that target complex diseases such as cancer and autoimmune disorders. Compass Therapeutics leverages its proprietary StitchMabsTM technology, which enables the development of bispecific and multispecific antibody therapeutics aimed at enhancing immune system response and improving patient outcomes.

Compass Therapeutics (CMPX) Earnings & Revenues

Historic Earnings Reports

CMPX Earnings Call

Q2 2025

0:00 / 0:00

CMPX Stock 12 Month Forecast

Average Price Target

$14.00

▲(159.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","25":"$25","6.25":"$6.25","12.5":"$12.5","18.75":"$18.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.25,12.5,18.75,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.46,6.886153846153846,8.312307692307693,9.73846153846154,11.164615384615384,12.59076923076923,14.016923076923078,15.443076923076923,16.869230769230768,18.295384615384616,19.72153846153846,21.147692307692306,22.573846153846155,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.46,6.116923076923077,6.773846153846153,7.430769230769231,8.087692307692308,8.744615384615384,9.401538461538461,10.058461538461538,10.715384615384615,11.372307692307691,12.029230769230768,12.686153846153845,13.343076923076922,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.46,5.809230769230769,6.158461538461538,6.507692307692308,6.856923076923077,7.206153846153846,7.555384615384615,7.904615384615385,8.253846153846155,8.603076923076923,8.952307692307691,9.301538461538462,9.650769230769232,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.46,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >